Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 15 h ago

Tarsus Pharmaceuticals, Inc.: Paradigm Biocapital Advisors LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Paradigm Biocapital Advisors LP amended its Schedule 13G filing on Tarsus Pharmaceuticals, disclosing a change in its beneficial ownership stake under SEC accession 0001104659-26-128301. The filing updates the investment firm's position in the biopharmaceutical company, though the amended document did not specify the exact size of the stake or the direction of the change. Schedule 13G amendments are typically filed by institutional investors when their ownership crosses or adjusts relative to the 5% threshold, making the disclosure a signal of shifting institutional interest in Tarsus. Investors will watch for further 13G or 13D filings to confirm whether Paradigm is building or trimming its position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Tarsus Pharmaceuticals, Inc., Paradigm Biocapital Advisors LP